Navidea raises $25M to market Lymphoseek

Navidea Biopharmaceuticals ($NAVB) has closed a $25 million debt financing with GE Capital, planning to use the funds to amp up commercialization for Lymphoseek, the company's FDA-approved cancer diagnostic tool. In addition, Navidea will put some of the cash toward its pipeline, which includes diagnostic imaging agents for Alzheimer's and Parkinson's. More

Suggested Articles

Digital molecule designer Insilico Medicine has launched a new preclinical research program focused on treatments for brain cancer.

Ortho Clinical Diagnostics has launched a new chemistry system to complete its integrated Vitros XT line of laboratory solutions.

Synthetic DNA weaver Twist Bioscience announced a handful of new collaborations this week amidst a $140 million raise from an underwritten offering.